Shareholders who lost money in American Depositary Receipts of Endava plc (NYSE: DAVA) should contact Wolf Haldenstein Immediately

Endava ADRs fell $0.68, or 24.37%, to $2.11 on September 22, 2026, after the company said its CFO was placed on administrative leave pending an independent investigation into accounting treatment of certain customer and supplier agreements. A securities class-action complaint alleges the company failed to disclose accounting-review concerns, risks to internal controls, and the resulting delay to fourth-quarter and full-year 2026 results; these are allegations, not established findings. The lead-plaintiff deadline is November 30, 2026.

Analysis

The investable signal is not the securities-law firm’s allegations; it is the auditor-triggered review of contract accounting, the CFO’s leave, and the delayed reporting. If the review expands beyond presentation or timing into revenue recognition, prior-period results or control deficiencies, the risk shifts from a one-off earnings reset to a longer credibility discount: investors may demand more evidence before underwriting guidance, while customers and staff could become more cautious if uncertainty persists. Any competitive share gains for other IT-services providers are conditional, not yet evidenced.

Near term, the 24% gap already reflects substantial uncertainty, so chasing a short risks a sharp relief rally on a narrow review or clean filing. Over the next 1–3 months, the key catalysts are the investigation’s scope, auditor conclusions, timing and completeness of financial statements, and any revised guidance. Over 6–18 months, unresolved controls or restatements could weigh on customer confidence and valuation even after the legal headline fades. The contrarian point: the complaint is promotional litigation material, not independent proof of fraud; however, dismissing the episode as merely legal noise would underweight the auditor concern. Falsifiers include a timely, unqualified filing with no material adjustments and clear remediation; thesis confirmation would be expanded accounting adjustments, restatement, further delay, or formal control findings.

Key Decisions for Investors

• For existing DAVA holders, reduce exposure to a size that can tolerate another disclosure-driven gap; do not treat the lawsuit announcement itself as incremental evidence beyond the underlying accounting review.
• Avoid initiating an outright short immediately after the sharp repricing. Reassess after the next company or auditor update; a risk-defined bearish options position is only worth considering if options liquidity and pricing are verified.
• Keep DAVA on an event-risk watch through the November 30 lead-plaintiff deadline, but prioritize the audit investigation and filing timetable over litigation headlines. Verify whether results are delayed again, whether prior periods are affected, and whether the auditor identifies a material weakness.
• A relief-rally thesis requires a complete, timely filing with no material accounting adjustment and credible control remediation. Further delay, restatement, or expanded control findings would invalidate that thesis and support reducing exposure further.